Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | JAK2 over exp |
Therapy | NVP-BSK805 + Paclitaxel |
Indication/Tumor Type | triple-receptor negative breast cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK2 over exp | triple-receptor negative breast cancer | sensitive | NVP-BSK805 + Paclitaxel | Preclinical - Pdx | Actionable | In a preclinical study, NVP-BSK805 with Abraxane (paclitaxel) inhibited tumor growth in patient-derived xenograft models of triple-negative breast cancer with JAK2 overexpression (PMID: 27075627). | 27075627 |
PubMed Id | Reference Title | Details |
---|---|---|
(27075627) | Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence. | Full reference... |